The Overall Survival of Patients Diagnosed With Unresectable Hepatocellular Carcinoma Under Real-life Clinical Practice in Asia Pacific Region
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatocellular Carcinoma
- Sponsor
- Humanity & Health Medical Group Limited
- Enrollment
- 5000
- Locations
- 3
- Primary Endpoint
- Overall survival
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China).
The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a diagnosis of unresectable hepatocellular carcinoma
- •Able to comprehend and provide written informed consent in accordance with institutional guidelines.
Exclusion Criteria
- •Patients not willing to participate and/or give their written informed consent.
Outcomes
Primary Outcomes
Overall survival
Time Frame: Up to 5 years
Overall survival (OS) is defined as the time (days) from the date of unresectable HCC diagnosis to the date of death, due to any reason. Patients alive or lost to follow-up at the time of analysis will be censored at their last date of follow-up
Secondary Outcomes
- Progression-free survival (PFS)(Up to 5 years)
- Time to progression (TTP)(Up to 5 years)
- Frequency and Severity of Adverse Events(Up to 5 years)
- Duration of treatment(Up to 5 years)